Concepedia

Author

Mark Sydenham

Institute of Cancer ResearchORCID

Also Known As

Alan Stewart, M Sydenham, M. A. Sydenham, M. Sydenham, M.A. Sydenham, Mark A Sydenham, Mark A. Sydenham, Mark Adrian Sydenham, Mark Sydenham

72

Publications

8.1K

Citations

24

H-Index

52

Concepts

All Affiliations

Institute of Cancer ResearchRoyal Marsden NHS Foundation TrustMount Vernon Cancer CentreUniversity Hospitals of North Midlands NHS TrustCheltenham General Hospital
MS

About

Mark Sydenham is an author at Institute of Cancer Research specializing in medicine, radiation oncology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

15

17

2.4K

2

Health Sciences

10

10

1.7K

3

Cell Biology

3

3

226

4

Natural Sciences

2

2

84

5

Cellular Physiology

1

1

142

Mark Sydenham

×

33

Publications

6.7K

Citations

23

H-Index

YearCitations

Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial

Christopher M. Nutting, James P. Morden, Kevin J. Harrington,

The Lancet Oncology

2011

1.7K

The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials

Joanne Haviland, John R. Owen, John Dewar,

The Lancet Oncology

2013

1.4K

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial

Adrian Murray Brunt, Joanne Haviland, Duncan Wheatley,

The Lancet

2020

1K

Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial

Charlotte E. Coles, Clare Griffin, Anna M. Kirby,

The Lancet

2017

589

Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization.

Stephen E. Fawell, R White, Susan Hoare,

Proceedings of the National Academy of Sciences

1990

402

Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer

Adrian Murray Brunt, Joanne Haviland, Mark Sydenham,

Journal of Clinical Oncology

2020

281

Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial

Adrian Murray Brunt, Duncan Wheatley, John Yarnold,

Radiotherapy and Oncology

2016

218

High Level Expression of the Humanized Monoclonal Antibody CAMPATH-1H in Chinese Hamster Ovary Cells

Martin Pagé, Mark Sydenham

Nature Biotechnology

1991

142

Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials

Joanne Haviland, Mariella Mannino, Clare Griffin,

Radiotherapy and Oncology

2017

101

Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial

Christopher M. Nutting, Laura Finneran, Justin Roe,

The Lancet Oncology

2023

93

Page 1